News Novo Nordisk fight with KBP Bio will go to arbitration Singapore court keeps an asset freeze on KBP Bio, saying the merits of its dispute with Novo Nordisk over a licensing deal must go to arbitration.
News AZ gets first okay for new hypertension drug baxdrostat AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.
News AZ uses a priority review voucher for baxdrostat filing Seeking a lead over rival Mineralys, AstraZeneca is using a priority review voucher for its US filing for uncontrolled hypertension drug baxdrostat.
News AHA: AZ's baxdrostat impresses in resistant hypertension AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.
News AHA: Cash for drug adherence study has disappointing result People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.
News George's triple therapy for hypertension hits mark in stroke George Medicines' new triple pill for hypertension delivers a much-needed win in a phase 3 trial in haemorrhagic stroke.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.